Letters Pfizer and pregabalin

Open letter to clinicians and pharmacists from Berkeley Phillips, UK medical director, and Seema Patel, established pharma medical director, Pfizer UK

BMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h3645 (Published 07 July 2015) Cite this as: BMJ 2015;351:h3645
  1. Berkeley Phillips, UK medical director1,
  2. Seema Patel, established pharma medical director1
  1. 1Pfizer, UK
  1. Berkeley.phillips{at}pfizer.com

There has been some discussion and media reporting about our patent for the use of Lyrica (pregabalin) in the treatment of pain over recent months.1 We recognise this has been the cause of concern for some of you, and we apologise if this has been the case. We hope this letter will help to bring further clarity and reassurance to all concerned.

We wish we had been able to explain this patent situation earlier and better. This was new territory for all of us and there was no system or policy in place to deal with it. We were finding our way, as was the NHS. Our intention was neither to cause confusion, nor to add to your workload. As a physician and pharmacist, respectively, we appreciate the work you are all doing under many, and often conflicting, pressures.

Ultimately, Pfizer’s goal is to discover and develop new drugs for …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe